Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company's proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues. The Company's most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in Phase 2 clinical development. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc.
Company profile
Ticker
ENTX, ENTXW
Exchange
Website
CEO
Adam Gridley
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Bio-Techne • Exelixis • Ginkgo Bioworks ...
SEC CIK
Corporate docs
Subsidiaries
Entera Bio Inc. ...
ENTX stock data
Latest filings (excl ownership)
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
23 Nov 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022
10 Nov 22
8-K
Other Events
6 Oct 22
8-K
Submission of Matters to a Vote of Security Holders
9 Sep 22
424B5
Prospectus supplement for primary offering
2 Sep 22
8-K
Entry into a Material Definitive Agreement
2 Sep 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
8-K
Entera Bio Provides Business Highlights and Financial Results for the Second Quarter 2022
11 Aug 22
8-K
Entera Bio Corporate PresentationAugust 2022
1 Aug 22
Transcripts
ENTX
Earnings call transcript
2022 Q1
18 May 22
ENTX
Earnings call transcript
2021 Q4
8 Mar 22
ENTX
Earnings call transcript
2021 Q2
16 Aug 21
ENTX
Earnings call transcript
2020 Q4
18 Mar 21
ENTX
Earnings call transcript
2020 Q3
19 Nov 20
ENTX
Earnings call transcript
2020 Q2
20 Aug 20
ENTX
Earnings call transcript
2020 Q1
21 May 20
ENTX
Earnings call transcript
2019 Q4
26 Mar 20
ENTX
Earnings call transcript
2019 Q3
21 Nov 19
ENTX
Earnings call transcript
2019 Q2
20 Aug 19
Latest ownership filings
4
ROGER GARCEAU
4 Jan 23
4
GERALD M LIEBERMAN
4 Jan 23
4
Ron Mayron
4 Jan 23
4
GERALD M OSTROV
4 Jan 23
4
Yonatan Malca
4 Jan 23
4
Sean Ellis
4 Jan 23
SC 13G/A
CENTILLION FUND INC.
18 Nov 22
SC 13G/A
CENTILLION FUND INC.
18 Nov 22
SC 13G/A
CENTILLION FUND INC.
18 Nov 22
4
Dana Yaacov-Garbeli
15 Nov 22
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 14.39 mm | 14.39 mm | 14.39 mm | 14.39 mm | 14.39 mm | |
| Cash burn (monthly) | 975.33 k | 881.17 k | 957.67 k | 1.17 mm | 399.33 k | |
| Cash used (since last report) | 4.24 mm | 3.83 mm | 4.17 mm | 5.10 mm | 1.74 mm | |
| Cash remaining | 10.15 mm | 10.56 mm | 10.22 mm | 9.29 mm | 12.65 mm | |
| Runway (months of cash) | 10.4 | 12.0 | 10.7 | 7.9 | 31.7 | |
Institutional ownership, Q3 2022
8.3% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 1 |
| Opened positions | 0 |
| Closed positions | 12 |
| Increased positions | 1 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 3.24 mm |
| Total shares | 2.40 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Centillion Fund | 2.40 mm | $3.24 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 2 Jan 23 | Sean Ellis | Stock Option (right to buy Ordinary Shares, par value NIS 0.0000769 per share | Grant | Acquire A | No | No | 0.73 | 89,041 | 65.00 k | 89,041 |
| 2 Jan 23 | Yonatan Malca | Stock Option Ordinary Shares, par value NIS 0.0000769 per share | Grant | Acquire A | No | No | 0.73 | 89,041 | 65.00 k | 89,041 |
| 2 Jan 23 | Gerald M Ostrov | Stock Option Ordinary Shares, par value NIS 0.0000769 per share | Grant | Acquire A | No | No | 0.73 | 89,041 | 65.00 k | 89,041 |
| 2 Jan 23 | Ron Mayron | Stock Option Ordinary Shares, par value NIS 0.0000769 per share | Grant | Acquire A | No | No | 0.73 | 89,041 | 65.00 k | 89,041 |
| 2 Jan 23 | Lieberman Gerald M | Stock Option Ordinary Shares, par value NIS 0.0000769 per share | Grant | Acquire A | No | No | 0.73 | 89,041 | 65.00 k | 89,041 |
News
Why Oblong Shares Are Trading Higher By 59%; Here Are 20 Stocks Moving Premarket
4 Jan 23
Why Foresight Autonomous Shares Jumped 33%; Here Are 83 Biggest Movers From Yesterday
17 Nov 22
Entera Bio And 2 Other Stocks Under $1 Insiders Are Aggressively Buying
16 Nov 22
Why Tattooed Chef Shares Dipped Around 15%; Here Are 95 Biggest Movers From Friday
14 Nov 22
Why Compass Shares Are Trading Higher By Over 56%? Here Are 63 Stocks Moving In Friday's Mid-Day Session
11 Nov 22